New Delhi, June 12, 2024.
Dr Reddy’s Laboratories Ltd on Wednesday said it has signed a licensing pact with US-based Ingenus Pharmaceuticals, LLC, to commercialise Cyclophosphamide injection used in treatment of cancer.
The company’s wholly-owned subsidiary Dr Reddy’s Laboratories Inc and Ingenus Pharmaceuticals, LLC have entered into license agreement, Dr Reddy’s Laboratories Ltd (DRL) said in a regulatory filing.
Subsequently, Dr Reddy’s Laboratories Inc (Dr Reddy’s USA) has licensed from Ingenus, the exclusive rights to commercialise Cyclophosphamide injection of strengths 500 mg/2.5mL; 1g/5mL; 2g/10mL in the US, it added.
